Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial

Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial

Summary: Background: Patients with type 2 diabetes and obesity have chronic activation of the innate immune system possibly contributing to the higher risk of hyperinflammatory response to SARS-CoV2 and severe COVID-19 observed in this population. We tested whether interleukin-1β (IL-1β) blockade u...

Full description

Bibliographic Details
Main Authors: Matthias Hepprich, Jonathan M. Mudry, Claudia Gregoriano, Francois R. Jornayvaz, Sebastian Carballo, Anne Wojtusciszyn, Pierre-Alexandre Bart, Jean-Daniel Chiche, Stefan Fischli, Thomas Baumgartner, Claudia Cavelti-Weder, Dominique L. Braun, Huldrych F. Günthard, Felix Beuschlein, Anna Conen, Emily West, Egon Isenring, Stefan Zechmann, Gabriela Bucklar, Yoann Aubry, Ludovic Dey, Beat Müller, Patrick Hunziker, Philipp Schütz, Marco Cattaneo, Marc Y. Donath
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:EClinicalMedicine
Subjects:
COVID-19
Diabetes
Obesitiy
IL-1beta
Inflammasome
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537022003790

Internet

http://www.sciencedirect.com/science/article/pii/S2589537022003790

Similar Items